4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
aTyr Pharma, Inc. (ATYR) operates in the Biotechnology industry and is headquartered in San Diego, United States with about 58 employees. Its market capitalization is roughly $46 million. In the fiscal year ended 2025-12-31, ATYR reported $0M in revenue and ($74M) in net income.
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States.
Interactive charts & full statements → Open the ATYR valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $10M |
| Operating Income (EBIT) | ($78M) | ($68M) | ($55M) | ($46M) |
| Net Income | ($74M) | ($64M) | ($50M) | ($45M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($11M) | ($15M) | ($27M) | ($20M) | ($16M) |
| Net Income | ($11M) | ($14M) | ($26M) | ($20M) | ($15M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $93M | $97M | $121M | $96M | — |
| Total Liabilities | $26M | $27M | $30M | $24M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ATYR viewer.
About TickerBase · Data methodology & sources